**Core Concept**
Multiple myeloma is a type of blood cancer characterized by the proliferation of malignant plasma cells in the bone marrow. The treatment of multiple myeloma often involves a combination of chemotherapy, targeted therapy, and immunotherapy to control disease progression and alleviate symptoms.

**Why the Correct Answer is Right**
Bortezomib (Boezomib) is a proteasome inhibitor that targets the 26S proteasome, a complex responsible for degrading ubiquitinated proteins in the cytosol and nucleus. By inhibiting the proteasome, bortezomib disrupts the cell cycle and induces apoptosis in malignant plasma cells, making it an effective treatment for multiple myeloma. Bortezomib is often used in combination with other agents such as dexamethasone and lenalidomide to achieve better clinical outcomes.

**Why Each Wrong Option is Incorrect**
**Option B:** Methotrexate is an antifolate drug that inhibits dihydrofolate reductase, an enzyme essential for DNA synthesis and repair. While methotrexate is used in the treatment of various cancers, including leukemia and lymphoma, it is not a first-line treatment for multiple myeloma.

**Option C:** Hydroxyurea is a ribonucleotide reductase inhibitor that interferes with DNA synthesis and repair. It is used in the treatment of certain types of cancer, including chronic myeloid leukemia and cervical cancer, but is not typically used in the treatment of multiple myeloma.

**Option D:** Ketoconazole is an antifungal agent that inhibits lanosterol 14α-demethylase, an enzyme involved in the biosynthesis of ergosterol. While ketoconazole has been used in the treatment of Cushing's syndrome due to its ability to inhibit steroidogenesis, it is not used in the treatment of multiple myeloma.

**Clinical Pearl / High-Yield Fact**
Bortezomib is a first-line treatment for multiple myeloma and is often used in combination with other agents to achieve better clinical outcomes. It is essential to monitor patients for potential side effects, including peripheral neuropathy and thrombocytopenia, when using bortezomib.

**✓ Correct Answer:** A. Boezomib